Barrett’s Esophagus with Dysplasia: Causes and Treatments

Barrett’s esophagus with dysplasia develops when chronic acid and bile reflux damages the lining of the lower esophagus so severely that the normal tissue is replaced by an abnormal, intestine-like lining, and that abnormal lining then accumulates precancerous cellular changes. The condition sits on a spectrum between garden-variety reflux damage and esophageal adenocarcinoma, and the grade of dysplasia (low or high) largely dictates how aggressively it needs to be treated. The good news is that treatments have improved dramatically over the past two decades, with endoscopic therapies now able to eliminate dysplasia in roughly nine out of ten patients without major surgery.

How Barrett’s Esophagus Forms

Your esophagus is normally lined with flat, layered cells called squamous epithelium. In people with long-standing gastroesophageal reflux disease, the constant backwash of stomach acid, pepsin, bile acids, and pancreatic enzymes overwhelms the esophagus’s built-in defenses. The mucosal lining gets injured, repairs itself, gets injured again, and eventually the body swaps in a different type of tissue altogether: columnar epithelium that resembles the lining of the intestine. This swap is called intestinal metaplasia, and it is what defines Barrett’s esophagus. Researchers believe the replacement cells arise from multipotent stem cells located either in the base of the normal esophageal lining or in the ducts of small glands beneath it.¹

Barrett’s tissue on its own is not cancer. But over time, continued reflux exposure and accumulated genetic damage can push these already-altered cells toward dysplasia, which means the cells have started looking and behaving abnormally under a microscope. Low-grade dysplasia is the earlier stage; high-grade dysplasia is the more advanced one, where cells look closer to cancerous. Neither stage is cancer yet, but the further along the spectrum you go, the higher the risk of progressing to esophageal adenocarcinoma.

Who Is at Risk

The strongest risk factors for developing Barrett’s esophagus are male sex, older age, a family history of the condition, long-duration reflux disease, smoking, and central obesity measured by waist-to-hip ratio.² Men are consistently at higher risk than women across populations. A longitudinal cohort study of patients with reflux found that male sex roughly doubled or tripled the odds of developing Barrett’s, and cumulative cigarette smoking and alcohol intake were independent risk factors during follow-up.³

The picture varies by population. A large Japanese cohort study confirmed male sex as an independent risk factor but found that body mass index, diabetes, current smoking, and heavy drinking were not significantly associated with Barrett’s after adjusting for other variables.⁴ This discrepancy likely reflects differences in the predominant type of Barrett’s seen in East Asian versus Western populations, as well as different baseline rates of obesity and reflux patterns. The takeaway is that while reflux is the common denominator everywhere, the relative importance of lifestyle factors depends on context.

How Fast Does Dysplasia Progress to Cancer

One of the most anxiety-producing aspects of a dysplasia diagnosis is the question of time. The overall progression rate from Barrett’s to esophageal adenocarcinoma is not enormous. A study examining progression across dysplasia grades found an overall annual incidence of under 1%, but the rate climbed with dysplasia severity: roughly 0.4% per year for non-dysplastic Barrett’s, about 1.4% per year for indefinite-for-dysplasia, and around 1.8% per year for low-grade dysplasia.⁵ High-grade dysplasia carries even steeper risk, which is why guidelines recommend active treatment rather than just watching and waiting.

These numbers are averages, and individual risk varies. The molecular profile of your Barrett’s tissue matters as much as the histologic grade. Mutations in the TP53 gene are among the strongest predictors of progression. TP53 mutations were found in nearly half of tissue samples from patients who eventually progressed, compared with only about 5% in non-progressors, corresponding to a roughly 14-fold increased risk of progression.⁶ A separate study confirmed that abnormal p53 staining on biopsy tissue strongly predicted progression regardless of what the pathologist classified the dysplasia grade as.⁷ This is particularly useful because pathologists sometimes disagree on dysplasia grades, so having a molecular marker that cuts through that ambiguity gives doctors an additional tool for risk-stratifying patients.

How Dysplasia Is Detected

Detecting dysplasia in Barrett’s tissue is trickier than it sounds. Dysplastic areas can be flat and nearly invisible during a standard endoscopy. The gold-standard approach is the Seattle protocol, where the endoscopist takes systematic biopsies every one to two centimeters throughout the Barrett’s segment in all four quadrants, plus targeted biopsies of anything that looks abnormal. A study comparing this systematic approach with technology-assisted targeted biopsies found that the Seattle protocol was responsible for diagnosing about 80% of dysplasia cases, and its advantage was most pronounced for low-grade dysplasia, which is harder to see with the naked eye.⁸

One limitation is that endoscopy itself is a barrier. It requires sedation, a specialist, and a hospital or ambulatory surgery center visit. A non-endoscopic screening tool called the Cytosponge has been developed as an alternative for initial screening. You swallow a small capsule attached to a string; the capsule dissolves, releasing a small sponge that collects cells from the esophagus as it is pulled back out. Those cells are then tested for a protein called trefoil factor 3, which is a marker of Barrett’s tissue. A meta-analysis found that for detecting clinically relevant Barrett’s segments, the Cytosponge had a sensitivity of about 81% and a specificity of about 89%.⁹ An earlier primary-care study found similar specificity and noted that patients preferred the Cytosponge to endoscopy, which is unsurprising.¹⁰ The Cytosponge is not yet widely used in routine practice everywhere, but it could substantially broaden access to screening, especially in primary care settings where patients would otherwise never be referred for endoscopy.

Radiofrequency Ablation

Radiofrequency ablation, or RFA, has become the dominant treatment for flat (non-nodular) dysplastic Barrett’s. A catheter with a balloon-mounted electrode array is placed against the Barrett’s lining and delivers controlled bursts of heat to destroy the abnormal tissue. The body then replaces it with normal squamous epithelium. A landmark randomized trial found that RFA eliminated dysplasia in about 90% of patients with low-grade dysplasia and 81% of those with high-grade dysplasia, compared with roughly 20% in sham-treated controls. Fewer patients who received ablation progressed to cancer as well, at about 1% versus 9% in the control group.¹¹

A systematic review and meta-analysis pooling data from multiple studies found that RFA achieved complete eradication of intestinal metaplasia in about 78% of patients and complete eradication of dysplasia in about 91%. Esophageal stricture, a narrowing that can cause swallowing difficulty, was the most common complication and occurred in around 5% of patients.¹² After initial eradication, intestinal metaplasia recurred in about 13% of patients, so ongoing surveillance remains important even after successful treatment.

Durability data are encouraging. A follow-up study of the original trial cohort found that after three years, dysplasia remained eradicated in about 98% and intestinal metaplasia in about 91% of treated patients, without maintenance ablation sessions. The annual rate of esophageal adenocarcinoma was low at about 0.55% per patient-year.¹³

Endoscopic Resection for Visible Lesions

When dysplastic Barrett’s contains a visible bump, nodule, or slightly raised area, the standard first step is endoscopic resection, where the abnormal tissue is physically cut or suctioned away rather than just burned. This serves a dual purpose: it removes the suspicious tissue and provides a large tissue specimen for pathologists to evaluate, which is far more informative than a small pinch biopsy. A meta-analysis comparing the two main resection techniques found that endoscopic submucosal dissection achieved en bloc removal (meaning the lesion is taken out in one piece) in about 98% of cases, versus about 37% for endoscopic mucosal resection. Both techniques achieved complete eradication of dysplasia in about 94% of cases.¹⁴ In practice, most centers use endoscopic mucosal resection for smaller Barrett’s-associated lesions because it is faster and technically simpler, and reserve submucosal dissection for larger or more complex nodules. Either approach is typically followed by RFA to treat any remaining flat Barrett’s tissue.

When Surgery Is Still Needed

Before endoscopic therapies matured, esophagectomy, the surgical removal of most of the esophagus, was the standard treatment for high-grade dysplasia. It is a major operation with real risks: prolonged hospital stays, possible complications, and lasting effects on eating and quality of life. A comparative effectiveness analysis found that for a typical patient, endoscopic therapy (resection plus ablation) yielded equivalent quality-adjusted life years compared with esophagectomy at substantially lower cost.¹⁵ However, the same analysis noted that patients with diffuse or ulcerated high-grade dysplasia are still better served by surgery. And a separate study confirmed that while endoscopic therapy carries a slightly higher risk of later tumor progression, esophagectomy is usually curative when needed.¹⁶ Surgery has shifted from being the default to being a well-defined backup for cases that endoscopic treatment cannot adequately handle, such as deeply invasive early cancer or widespread disease that resists ablation.

Cryotherapy as a Rescue Option

Some patients do not respond fully to radiofrequency ablation. In these cases, cryotherapy, which uses liquid nitrogen or compressed carbon dioxide to freeze and destroy residual Barrett’s tissue, can serve as a second-line treatment. A study of patients who had failed RFA found that cryotherapy achieved complete eradication of dysplasia at high rates, though complete eradication of intestinal metaplasia was somewhat lower at about 50%, compared with the 78% typically seen with RFA in treatment-naïve patients.¹⁷ The option matters because it gives doctors a viable plan B for patients who might otherwise face surgery simply because their first ablation approach did not work.

The Role of Acid Suppression

Proton pump inhibitors are prescribed to virtually every Barrett’s patient to control acid reflux. Beyond symptom relief, there is evidence they may slow the progression to cancer. A meta-analysis found that PPI use was associated with roughly a 53% reduction in the risk of progressing from Barrett’s to high-grade dysplasia or adenocarcinoma.¹⁸ The evidence is observational, however, and a separate meta-analysis examining whether acid suppressants reduce the absolute risk of developing adenocarcinoma found that the association with PPIs did not reach statistical significance overall.¹⁹ In practice, PPIs remain standard care because they manage reflux symptoms and esophageal healing, and likely provide some degree of protection even if the precise cancer-prevention benefit remains hard to pin down.

Chemoprevention with Aspirin and Statins

There has been considerable interest in whether common medications could lower cancer risk in Barrett’s patients. In observational studies, statin use was associated with roughly a 41% decrease in the risk of developing adenocarcinoma among Barrett’s patients, though the number of people who would need to take a statin to prevent one cancer was estimated at about 389.²⁰ Non-steroidal anti-inflammatory drugs, especially aspirin, have shown a similar association. A review found that NSAIDs were linked to about a 41% reduction in adenocarcinoma incidence in Barrett’s patients, and the combination of an NSAID plus a statin was associated with an even larger reduction. But the same review stressed that the epidemiological studies are small and underpowered, and that NSAIDs carry meaningful gastrointestinal and cardiovascular toxicity risks of their own.²¹ At present, neither statins nor aspirin are prescribed specifically for Barrett’s chemoprevention. If you already take them for heart disease, the possible esophageal benefit is a bonus, but starting them solely for Barrett’s is not currently recommended.

Surveillance After Successful Treatment

Even after dysplasia has been eliminated, the esophagus needs ongoing monitoring because the abnormal tissue can come back. American Gastroenterological Association guidelines recommend surveillance endoscopies at 3, 6, and 12 months after treatment is complete, and then annually after that.²² That schedule is intensive, especially in the first year. An international cohort study explored whether it could be relaxed without missing important recurrences. For patients who originally had high-grade dysplasia, a slightly less frequent schedule (at 6, 12, 18, and 24 months, then annually) still caught all dysplastic recurrences within six months while cutting the number of endoscopies by about a third.²³ For those originally treated for low-grade dysplasia, surveillance at 1, 2, and 4 years struck a reasonable balance. These findings suggest that post-treatment surveillance can be individualized based on the original severity.

The Microbiome Connection

An emerging area of research involves the role of esophageal bacteria and bile acids in Barrett’s progression. The lower esophagus has its own distinct microbial community, primarily made up of bacteria that originate in the mouth. In Barrett’s tissue, this microbial community shifts, and those shifts appear to be associated with changes in gene activity that promote inflammation and cell growth. One study found that the bacterium Streptococcus, which was increased in Barrett’s tissue, correlated with higher expression of inflammatory signals. Meanwhile, a decrease in another bacterium, Actinomyces, was associated with progressive stages of dysplasia and changes in hundreds of genes, including upregulation of energy-producing pathways linked to cancer growth.²⁴ Certain bile acids refluxed into the esophagus, particularly a conjugated secondary bile acid called GDCA, were linked to decreased expression of normal esophageal tissue markers and downregulation of cell-differentiation pathways, essentially nudging cells away from normal behavior.²⁵ None of this has translated into microbiome-targeted treatments yet, but it points toward possible future interventions and helps explain why acid suppression alone may not fully prevent progression.

Artificial Intelligence in the Endoscopy Suite

One persistent challenge in Barrett’s management is that dysplasia can be subtle enough to escape even an experienced endoscopist’s eye. Artificial intelligence tools are being developed to help. A pilot study using a convolutional neural network to analyze endoscopy images reported that the AI detected early dysplasia with about 96% sensitivity and 94% specificity, and could draw a localization box around the suspicious area in real time.²⁶ These tools are not replacing endoscopists but rather serving as a second set of eyes, flagging areas that might otherwise be overlooked. The technology is still in relatively early validation, and performance in real-world clinical settings tends to be somewhat lower than in curated image databases. But the trajectory is clear: AI-assisted endoscopy is likely to become part of standard Barrett’s surveillance within the next several years, potentially reducing the rate of missed dysplasia.

Quality of Life and the Psychological Burden

Living with a diagnosis of dysplastic Barrett’s carries a psychological weight that is easy to underestimate. Many patients worry about cancer risk, and that worry can affect daily life, work, and mental health. A randomized trial comparing RFA with sham treatment found that patients who received ablation had significantly less cancer-related worry, less depression, less stress, and less impact on their daily quality of life than those who underwent sham treatment.²⁷ A separate multicenter trial in patients with low-grade dysplasia found that those who underwent ablation perceived their disease as less threatening, reported fewer symptoms, and had fewer concerns about their condition compared with those who were monitored through surveillance alone.²⁸ These findings have been part of the argument for treating low-grade dysplasia rather than simply watching it, a practice that was debated for years but has increasingly shifted toward favoring treatment.

Screening Cost-Effectiveness and Who Benefits Most

Screening everyone with reflux for Barrett’s and dysplasia is not equally worthwhile across all populations. A comparative cost-effectiveness analysis using three simulation models found that the optimal screening approach depends heavily on sex and race. For white men with reflux symptoms, screening at ages 45 and 60 was the most cost-effective strategy. For Black men with reflux symptoms, a single screening at age 55 was favored. For women of any background, screening was not found to be cost-effective, and some screening strategies for Black women were actually associated with net harm.²⁹ These results reflect the fact that Barrett’s and esophageal adenocarcinoma are far more common in men, so the yield of screening programs is substantially lower in women. For ongoing surveillance after Barrett’s is already diagnosed and treated, a large randomized trial found that scheduled two-yearly endoscopy cost over $115,000 per quality-adjusted life year gained compared with endoscopy only when symptoms prompted it, making routine scheduled surveillance unlikely to be cost-effective for patients with non-dysplastic Barrett’s.³⁰ The economics reinforce the clinical message: intensive surveillance should be directed at the patients most likely to benefit, primarily those with confirmed dysplasia or other high-risk features, rather than applied uniformly to everyone carrying the Barrett’s diagnosis.